Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Muromonab CD3 (Primary) ; Aldesleukin; Sargramostim
- Indications Neuroblastoma; Osteosarcoma
- Focus Adverse reactions
- 04 Jun 2019 Results (n=9; as of Dec 2017) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 25 Jan 2019 Planned End Date changed from 1 May 2018 to 1 Dec 2019.
- 25 Jan 2019 Planned primary completion date changed from 1 May 2018 to 1 Dec 2019.